Latest News for: cdk2

Edit

World's First CDK2/4/6 Inhibitor Approved for Marketing, Culmerciclib Capsules (Saitanxin®) Reshape the Breast Cancer Treatment Landscape (Sino Biopharmaceutical Limited)

Public Technologies 16 Dec 2025
World's First CDK2/4/6 Inhibitor Approved for Marketing, Culmerciclib Capsules (Saitanxin®) Reshape the Breast Cancer Treatment Landscape ... Culmerciclib is a First-in-Class (FIC) CDK2/4/6 inhibitor globally.
Edit

World’s first CDK2/4/6 inhibitor approved in China

China Daily 12 Dec 2025
The world's first CDK2/4/6 inhibitor, developed by Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical, was officially approved for market launch on Thursday. CDK2/4/6 ...
Edit

NiKang Therapeutics Presents Discovery of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 ...

The Galveston Daily News 11 Dec 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Dec 11, 2025-- ....
Edit

Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium

Pharmiweb 11 Dec 2025
... (CDK2) selective inhibitor ... “CDK2 has emerged as an important resistance mechanism in patients with HR+/HER2- breast cancer, especially for patients who progress on CDK4/6 inhibitors,” said Alberto J.
Edit

Eilean Therapeutics Presents Novel, Selective, Brain-Permeable CDK2 Inhibitor for Treatment of CCNE1-Dependent Cancers

PR Newswire 16 Oct 2025
Eilean plans to present the drug candidate data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and to advance this highly selective CDK2 inhibitor into a First-in-Human clinical study in Q4 2025.
  • 1

Article Search

tools
×
×
×
×